Abstract
The EVIDENCE trial demonstrated that interferon (IFN) beta-1a, 44 mcg subcutaneously (sc) three times weekly (tiw) (Rebif), was significantly more effective than IFN beta-1a, 30 mcg intramuscularly (im) once weekly (qw) (Avonex), in reducing relapses and magnetic resonance imaging (MRI) activity in patients with relapsing-remitting multiple sclerosis at both 24 and 48 weeks of therapy. We now present final comparative data on these patients, showing that the superior efficacy of IFN beta-1a, 44mcg sc tiw, for relapse measures and MRI activity, compared with IFN beta-1a, 30mcg im qw, was sustained for at least 16 months. The development of antibodies to IFN was associated with reduced efficacy on MRI measures and fewer IFN-related adverse events, but did not have an impact on relapse outcomes.
Publication types
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic / administration & dosage
-
Adjuvants, Immunologic / adverse effects
-
Antibodies / blood
-
Antibodies / immunology
-
Central Nervous System / drug effects*
-
Central Nervous System / immunology
-
Central Nervous System / pathology
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Humans
-
Injections, Intramuscular
-
Injections, Subcutaneous
-
Interferon beta-1a
-
Interferon-beta / administration & dosage*
-
Interferon-beta / adverse effects
-
Interferon-beta / immunology
-
International Cooperation
-
Magnetic Resonance Imaging
-
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
-
Multiple Sclerosis, Relapsing-Remitting / immunology
-
Multiple Sclerosis, Relapsing-Remitting / physiopathology
-
Secondary Prevention
-
Time
-
Time Factors
-
Treatment Outcome
Substances
-
Adjuvants, Immunologic
-
Antibodies
-
Interferon-beta
-
Interferon beta-1a